esophageal cancer esophageal cancer
Conditions
Interventions
None listed
Sponsors
Kei Muro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with metastatic or recurrent esophageal squamous or adenosquamous cancer from January 1, 2013 to December 31, 2018 2. Age: 20 years or older 3. Patients in the above categories (1) to (4) of patients eligible for chemotherapy for esophageal cancer from January 2013 to the end of December 2018 who have received chemotherapy for metastasis or recurrence 4. Patients from whom appropriate consent is obtained (see General Informed Consent) All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study.
Exclusion criteria
Exclusion criteria: Patients who were registered in a clinical study at the time of the first chemotherapy treatment for metastatic or recurrent esophageal cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the patterns of treatment in patients who received a histological diagnosis of esophageal cancer (squamous, adenosquamous) who started chemotherapy for metastatic or recurrent esophageal cancer from January 1, 2013 to December 31, 2018. | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, clinical course (response rate, recurrence or metastasis, duration) and timings by type of chemotherapy, factors affecting outcomes | — |
Contacts
Public ContactShigenori Kadowaki
Department of Clinical Oncology, Aichi Cancer Center
Outcome results
None listed